welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, today announced The New England Journal of Medicine (NEJM) has published results from its landmark FAP-310 Phase 3 clinical trial of CPP-1X/sul as a pharmaco-preventive treatment for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Standard of care is surgery as there are no approved drugs for FAP.
The FAP-310 Phase 3 trial compared the performance of the combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul), to each single agent alone in delaying progression to an FAP-related clinical event, such as surgery. The trial enrolled 171 patients and was conducted over many years where patients received daily treatment for 2-4 years. It was the largest prospective controlled study ever performed in FAP, and the only clinical event driven trial ever conducted.
expertly curated content related to this topic
-
Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Survei...The primary objective of this chart revi...
-
Ileal Pouch-Anal Anastomosis RegistryLittle is known about the factors that p...
-
Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
-
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisDuodenal carcinomas are the leading caus...
-
Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?Total proctocolectomy with ileal pouch a...